-
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
•
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05 million (USD 136.9 million) in H1 2022, with net losses of RMB 912.4 million (USD 132 million). R&D spending rose 12% YOY to RMB 1.06 billion (USD 153.6 million), while cash reserves stood at RMB…
-
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
•
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang, Suzhou, China, announced the completion of a Phase I study for CBP-174, its small-molecule H3 receptor antagonist. The drug is being developed to treat pruritus (itch) associated with allergic and inflammatory skin diseases, including atopic…
-
RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China
•
US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company, as its exclusive distributor in China. MBL will handle sales and distribution of RoosterBio’s expansion media, exosome collection media, bioreactor media, and genetic engineering media to local clients. Product PortfolioRoosterBio’s engineered media are used in…
-
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
•
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Jardiance (empagliflozin), an SGLT2 inhibitor, to treat heart failure in adult patients with preserved ejection fraction (HFpEF). Previously approved in China for type 2 diabetes and heart failure with…
-
E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs
•
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised RMB 100 million (USD 14.5 million) in a Series A financing round. The round was led by M Momentum Venture and included contributions from Tailong Capital, Hangzhou Linping State-owned Capital Investment, and Hangzhou Jintou Industry…
-
Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise to promote its 13-valent and 23-valent pneumonia vaccines in the Philippines. The collaboration aims to enhance regulatory filing, promotion, distribution, marketing, and sales, increasing accessibility and affordability in the Philippines and other emerging markets. Vaccine…
-
MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results
•
China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022, with revenues of USD 405 million, up 10.1% year-on-year (YOY) excluding exchange rate impacts. The growth was driven by strong performance in key business segments despite COVID-19-related challenges. Business Segment Highlights Financial PerformanceThe company reported…
-
Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China
•
US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration (NMPA) has approved an expanded indication for its Gardasil 9-valent human papillomavirus (HPV) vaccine. The vaccine, initially approved for females aged 16–26, can now be administered to females aged 9–45. Vaccine Details Epidemiological Context Vaccination…
